Photocure ASA: Renewal of market maker agreement

Published: 5 April 2013Financial Investment & Stock

Oslo, Norway, 5 April 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces that its market maker agreement with SpareBank1 Markets will be replaced with a similar market maker agreement with DNB Markets with effect as of 21 May 2013.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 50 55 000, Email: ed@photocure.no

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

News and events

8 February 2023

New study publication reinforces the clinical benefits of Blue Light Cystoscopy in the ASC setting; supports ongoing initiatives to further improve reimbursement

Bladder Cancer: New Meta-analysis

15 December 2022

Photocure Partner Asieris announces First Patient treated in Hexvix Real-world Evidence study in Hainan, China

12 December 2022

Photocure to participate in the NALSC and DNB Healthcare Conferences in December

5 December 2022

New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO Meeting

5 December 2022

Photocure: CMS improves Medicare reimbursement for Blue Light Cystoscopy with Cysview and expands access in the surveillance setting

7 November 2022

Photocure Partner Asieris announces 1[st] Patient enrolled in Hexvix Phase III trial in China

4 November 2022

Photocure ASA: Results for the third quarter of 2022

2 November 2022

Photocure ASA: Invitation to presentation of third quarter 2022 financial results

25 October 2022

Data presented at the International Bladder Cancer Network (IBCN) meeting demonstrate a reduction in the risk of recurrence with the use of BLC

Photocure Announces the Commercial Availability of Karl Storz’s New Blue Light System in the U.S.

28 September 2022

New study demonstrates that tumor removal in the outpatient setting is as good as TURBT under general anesthesia

20 September 2022

Photocure Partner Asieris announces coverage of Hexvix by the Lecheng Global Specialty Drug Insurance

15 September 2022

Bladder Cancer technology: New KARL STORZ Blue Light Cystoscopy system featured during E-Masterclass in Urology

8 September 2022

Subscribe to our newsfeed and be kept up to date with the latest Photocure company news

GLOBAL HEADQUARTERS

Photocure ASA
Hoffsveien 4
0275 Oslo
Norway

E-mail: info@photocure.no

NORTH AMERICA

Photocure INC
202 Carnegie Center
Suite 101, Princeton,
NJ 08540, USA

E-mail: info@photocure.com

EUROPE

Photocure GmbH
Marc-Chagall-Str. 2
40477 Düsseldorf
Germany

E-mail: kontakt@photocure.com

Follow us

Privacy Policy Terms of use

© Photocure 2025

Key InformationProviding an update on the XYZ incident

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do